Navigation Links
Cell Genesys to Present at the BIO CEO and Investor Conference
Date:2/4/2008

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the BIO CEO and Investor Conference in New York, New York, on Monday, February 11, 2008 at 11:00 a.m. ET.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Cell Genesys website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 72 hours following the presentation. To access the replay, go to the Investor Relations section of the website.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Contact:

Susan Ferris

Investor Relations'/>"/>

SOURCE Cell Genesys
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Cell Genesys to Present at the BIO Investor Forum
3. Cell Genesys to Webcast Third Quarter 2007 Conference Call
4. Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
5. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
6. Avicena Group to Present at Noble Financial Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CEL-SCI to Present at the Noble Financial Conference
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Altamonte Springs, FL (PRWEB) March 05, 2015 ... Jamie Damm for the position of Vice President of ... support managed care relationships for one of the nation’s ... Seattle, brings more than 15 years of specialty pharmacy ... Previously Damm worked with Raptor Pharmaceuticals, Vertex Pharmaceuticals, and ...
(Date:3/5/2015)... Bi-Biomics today announced a discovery ... additive. The improvement in histological quality provided the ... in all daughter cells. , After processing with ... analyzed at 1000-1600x using light microscopy. Phylogenetic ... all daughter cells displayed predominant binary features --- ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 North ... Pierre Noel, M.D., Professor of Medicine, Mayo Clinic ... Company’s Board of Directors. , Entegrion’s ... extremely fortunate to have Dr. Noel, a distinguished ... healthcare organization, join Entegrion’s Board. His expertise in ...
(Date:3/5/2015)... TORONTO , March 5, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... Rice , Ph.D., Chairman, President and Chief Executive Officer, ... on Tuesday, March 10 th at 9:30 a.m. ... Niguel, CA. Dr. Rice will provide a ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3
... Today a promising young,scholar in bioethics, Dr. Jorge ... Award in Bioethics for his proposed research and,its ... Latin America during,the 27th Pan American Sanitary Conference ... the Pan American Health and,Education Foundation (PAHEF), presented ...
... and NUTLEY, N.J., Oct. 1 This month,Med ... business and,marketing publications, selected Roche out of 50 ... This marks the first time Roche has,received this ... focus on innovation-driven,healthcare as demonstrated by its top ...
... - New Product Under Development for the ... 28 European Countries DAIICHI SANKYO EUROPE GmbH has ... antihypertensive medication. It is a fixed combination,(CS-8663) of two ... antagonist Amlodipin. When approved, the new combination for ...
Cached Biology Technology:Prestigious Bioethics Award for Scholar from Mexico 2Med Ad News Honors Roche as 'Company of the Year' 2Med Ad News Honors Roche as 'Company of the Year' 3DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin 2
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... Conn. , Jan. 28, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... at the upcoming RedChip Global Online CEO Conference on ... Gino Pereira , CEO of NXT-ID ... its lead product, the Wocket smart wallet and its ...
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... 10, 2011The mega-mergers of 2009 did not continue into 2010. ... price tag of more than $40 billion, only last year,s ... of reported deals conducted by Genetic Engineering & Biotechnology News ... the year, sanofi-aventis, move to buy Genzyme, is still being ...
... reports that several herbicides used on corn also have ... Miscanthus), a potential bioenergy feedstock. "No herbicides are ... biomass," said Eric Anderson, an instructor of bioenergy for ... of Illinois. "Our research shows that several herbicides used ...
... 20,000 to 30,000 genes (the number is hotly contested), but ... proteins. It,s the protein molecules that domost of the work ... from the Greek prota, meaning "of primary importance." Proteins ... of usually fold spontaneously into what is called their "native ...
Cached Biology News:GEN reports on biotech acquisition deals in 2010 that topped $1 billion 2Miscanthus has a fighting chance against weeds 2New method takes snapshots of proteins as they fold 2New method takes snapshots of proteins as they fold 3New method takes snapshots of proteins as they fold 4New method takes snapshots of proteins as they fold 5